Literature DB >> 1695118

Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases.

Y S Venkatesh1, N G Ordonez, P N Schultz, R C Hickey, H Goepfert, N A Samaan.   

Abstract

One hundred twenty-one cases of anaplastic carcinoma of the thyroid treated at M.D. Anderson Cancer Center, Houston, were reviewed. Anaplastic carcinoma is a rapidly growing neoplasm with a dismal prognosis. The mean survival of our patients was 7.2 +/- 10 months. A significant percentage of our patients (35%) had areas of well-differentiated thyroid carcinoma elsewhere, supporting the hypothesis that anaplastic thyroid carcinoma arises from preexisting well-differentiated thyroid carcinoma. Twenty-four of 30 tumors analyzed (84%) stained for keratin, 28 (93.3%) stained for vimentin, and ten (33%) stained for epithelial membrane antigen. Younger patients lived longer than older patients, and patients whose disease was earlier-stage at presentation responded better than patients with metastases at presentation. Radical surgery alone did not significantly increase survival duration over less radical surgery. The role of multimodality therapy needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1695118     DOI: 10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  96 in total

Review 1.  Thyroid cancer surgery.

Authors:  R Udelsman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 3.  Anaplastic thyroid carcinoma.

Authors:  P I Haigh
Journal:  Curr Treat Options Oncol       Date:  2000-10

Review 4.  Cytopathologic diagnosis of fine needle aspiration biopsies of thyroid nodules.

Authors:  Evangelos P Misiakos; Niki Margari; Christos Meristoudis; Nickolas Machairas; Dimitrios Schizas; Konstantinos Petropoulos; Aris Spathis; Petros Karakitsos; Anastasios Machairas
Journal:  World J Clin Cases       Date:  2016-02-16       Impact factor: 1.337

5.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

6.  Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.

Authors:  Akira Yoshida; Kiminori Sugino; Iwao Sugitani; Akira Miyauchi
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

7.  Surgically resected undifferentiated carcinoma with osteoclast-like giant cells of the periampullary region involving the orifice of the papilla of Vater: Report of a case.

Authors:  Gaku Matsuzawa; Ken Shirabe; Tomonobu Gion; Eiji Tsujita; Masafumi Ooya; Kiyoshi Kajiyama; Takashi Nagaie
Journal:  Surg Today       Date:  2010-03-26       Impact factor: 2.549

8.  Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.

Authors:  Bin Xu; Talia Fuchs; Snjezana Dogan; Iñigo Landa; Nora Katabi; James A Fagin; R Michael Tuttle; Eric Sherman; Anthony J Gill; Ronald Ghossein
Journal:  Thyroid       Date:  2020-05-08       Impact factor: 6.568

9.  Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.

Authors:  J Akaishi; M Onda; J Okamoto; S Miyamoto; M Nagahama; K Ito; A Yoshida; K Shimizu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-28       Impact factor: 4.553

10.  Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Authors:  R C Smallridge; J A Copland; M S Brose; J T Wadsworth; Y Houvras; M E Menefee; K C Bible; M H Shah; A W Gramza; J P Klopper; L A Marlow; M G Heckman; R Von Roemeling
Journal:  J Clin Endocrinol Metab       Date:  2013-04-15       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.